The models offered by GE are used to study the cardiotoxic effects of lead molecules at an early phase of drug discovery. Cardiomyocytes provide a sensitive and robust approach for screening new chemical entities for potential cardiotoxic liabilities and gaining early insight into their mechanisms of toxicity. It focuses on developing innovative human cell-based assays and models to assist drug discovery and predictive toxicity screening.